NCT03723746View on ClinicalTrials.gov

A Study to Evaluate the Safety and Tolerability of JNJ-67670187 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

October 25, 2018

Primary Completion Date

December 16, 2019

Study Completion Date

December 16, 2019

Conditions
Healthy
Interventions
BIOLOGICAL

JNJ-67670187

Participants in Cohorts 1, 3 and 4 will receive Dose 1 and participants in Cohorts 2, 5, 6, 7, 8 and 9 will receive Dose 2.

BIOLOGICAL

Placebo

Participants will receive matching placebo in all cohorts.

Trial Locations (2)

2170

Clinical Pharmacology Unit, Merksem

9728 NZ

PRA Health Sciences Onderzoekscentrum Groningen, locatie Martini, Groningen

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT03723746 - A Study to Evaluate the Safety and Tolerability of JNJ-67670187 in Healthy Participants | Biotech Hunter | Biotech Hunter